N/A N=25 Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer
Glottic Carcinoma
Primary: Number of Patients With Local Failure Following SABR Treatment of Early Glottic Larynx Cancers — 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
Laryngeal Cancer
Primary: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment — 27; 12 Participants
Phase 2 N=9 A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
Head and Neck Cancer
Primary: Number of Participants With Treatment-Related Grade 3 or 4 Adverse Events as Assessed by CTCAE V4.0 — 2 Participants
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Phase 2 N=6 Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Head and Neck Cancer
Primary: Median Laryngectomy-free Survival (LFS) — 11.1 months
N/A N=55 Phonatory Movement of the Pharyngoesophageal Mucosa in Laryngectomy Patients
Larynx Cancer · Laryngectomy; Status
Primary: High Speed Video Endoscopy Recordings — 53; 2; 2; 38 Participants
Phase 2 N=30 Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer
Oropharyngeal Dysphagia · Oropharyngeal Cancer
Primary: Optimal Respiratory - Swallow Phase — 43; 86; 88.1 percentage of swallows
N/A N=278 Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
Recurrent Head and Neck Cancer
Primary: Disease-free Survival at 2 Years — 111 Participants
N/A N=12 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Duration of Local Control — 4.6 number of months to local failure
N/A N=170 Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
Head and Neck Cancer · Oropharyngeal Cancer · Hypopharyngeal Cancer
Primary: Number of Participants With Adequate Exposure and Access to Oropharyngeal and Hypopharyngeal Head and Neck Lesions — 147; 23 participants
Phase 2 N=15 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma
Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants
N/A N=25 Low-Level Laser in Head and Neck Chronic Lymphedema
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Total Severity of External Lymphedema and Fibrosis (LEF) — 5.42; 4.08; 3.22; 4.62 score on a scale
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
N/A N=112 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Phase 2 N=114 De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 2 N=60 Treatment of Head & Neck Cancer With Chemotherapy and Radiation
Head and Neck Cancer
Primary: Two-Year Progression Free Survival (PFS) Probability, the Percentage of Patients Estimated to be Alive Without Worsening of Their Disease Two Years After Beginning…
Phase 2 N=26 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
N/A N=4 CPAP to Improve Swallow Function Post Total Laryngectomy
Oropharyngeal Dysphagia · Laryngectomy; Status
Primary: Total Pharyngeal Transit Time (With CPAP) — 10.18 seconds — p=<0.05
N/A N=33 Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study
Oropharyngeal Cancer
Primary: Performance — 0 Participants
Phase 2 N=60 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
Oropharyngeal Cancer
Primary: Percentage of Participants With Local Control — 97.9 percentage of patients
Phase 2 N=25 High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
Head and Neck Cancer
Primary: Survival Rate of Patients — 33 months
Phase 2 N=45 De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Pathologic Complete Response Rate After De-escalated CRT in HPV-positive and/or p16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC). — 37 Participants
N/A N=12 Low-Level Laser in Treatment of Head and Neck Lymphedema: A Pilot Study
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Number of Participants Consented and Enrolled in Study — 12 Participants
Phase 2 N=127 TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Non-HPV Locally Advanced Head and Neck Cancer
Primary: Percentage of Participants Alive Without Progression (Progression-free Survival) — 34.6; 43.1 percentage of participants — p=0.3436
Phase 2 N=33 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
Phase 2 N=21 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Phase 2 N=34 Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage